-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $23

Benzinga·05/19/2025 17:33:44
Listen to the news
Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $20 to $23.